Brent A. Hanks - Concepedia

Author

Brent A. Hanks

Also Known As

B. A. Hanks, B. Hanks, B.A. Hanks, BRENT A. HANKS, Brent A Hanks, Brent A. Hanks, Brent Allen Hanks, Brent Hanks, Brian Gastman, Christine Xiao

165

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University University of North Carolina at Chapel Hill Moffitt Cancer Center Duke University Hospital

About

Brent A. Hanks is an author at Duke Medical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.6K
2	Natural Sciences	2	2	89
3	Engineering	1	1	36
4	Health Sciences	1	1	23
5	Allergy	1	1	59

Brent A. Hanks

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? John H. Strickler, Brent A. Hanks, Mustafa Khasraw Clinical Cancer Research	2020	405
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Journal of Clinical Oncology	2019	386
Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization Fei Zhao, Christine Xiao, Kathy S. Evans, Immunity Signal TransductionSignaling PathwayMolecular PathwayParacrine Wnt5a-β-catenin SignalingDendritic Cell Tolerization	2018	287
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy Balamayoora Theivanthiran, Kathy S. Evans, Nicholas C. DeVito, Journal of Clinical Investigation ImmunologyImmunotherapy ResistanceImmunotherapeuticsPmn-mdsc Tumor InfiltrationImmune Cell Therapy	2020	235
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy Alisha Holtzhausen, Fei Zhao, Kathy S. Evans, Cancer Immunology Research T-regulatory CellImmunologyImmune RegulationImmunoeditingImmunologic Mechanism	2015	175
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Journal for ImmunoTherapy of Cancer	2021	137
Stromal Fibroblasts Mediate Anti–PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma Fei Zhao, Kathy S. Evans, Christine Xiao, Cancer Immunology Research	2018	116
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets Nina Bhardwaj, Philip Friedlander, Anna C. Pavlick, Nature Cancer VaccinationDendritic Cell SubsetsAnti-dec-205-ny-eso-1 VaccineImmunologyTherapeutic Vaccine	2020	115
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment Brent A. Hanks, Alisha Holtzhausen, Katherine S. Evans, Journal of Clinical Investigation Tgfbr3 ExpressionT-regulatory CellImmune RegulationImmunologyImmunoediting	2013	113
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy Jared R. Lowe, Daniel J. Perry, April K.S. Salama, Journal for ImmunoTherapy of Cancer	2016	107

Page 1